Alex Goldberg

Atmel Corporation (NASDAQ:ATML) and Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/10/2014 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Atmel Corporation (NASDAQ:ATML) and Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Atmel Corporation (NASDAQ:ATML) a company that designs, develops, manufactures, and sells semiconductor integrated circuit products is currently up (+2.96%) on 3,748,463 shares traded. Atmel Corporation (NASDAQ:ATML) is currently up (+31.24%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Atmel Corporation (NASDAQ:ATML)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) a development stage biopharmaceutical company that focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry is currently up (+8.71%) on 656,774 shares traded after Intercept Announced to Present at Leerink Global Healthcare Conference in New York on Thursday, February 13, 2014. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is currently up (+1175.61%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com